Diagnosis and management of osteoporosis-full guideline

South African Medical Journal

Volumn 90, Issue 9 II, 2000, Pages 907-944

  Hough, S ^a   Mahlati, M P ^a  

^a South African Medical Association   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; FLUORIDE; HORMONE; PHYTOESTROGEN; RALOXIFENE; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; TIBOLONE; VITAMIN D;

AGE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CASE FINDING; CAUCASIAN; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENSITOMETRY; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNIC GROUP; EXERCISE; FALLING; FEMALE; FRACTURE; GENDER; HEALTH STATUS; HIP; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MALE; MEASUREMENT; MENOPAUSE; METHODOLOGY; OSTEOPENIA; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK FACTOR; SMOKING CESSATION; SPINE; VERTEBRA FRACTURE;

EID: 0033810238     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (166)

1. Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis
2. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
3. Involutional osteoporosis
4. Bone remodelling: Relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures
5. Vertebral fracture assessment using a semi-quantitative approach
6. Comparison of a semi-quantitative and a quantitative method for assessing vertebral fractures in osteoporosis
7. Assessing vertebral deformities
8. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
9. Prevalent vertebral fractures predict clinical fractures in postmenopausal women
10. Bone density in ageing Caucasian and African populations
11. Differences in mineral homeostasis, volumetric bone mass and femoral neck axis length in black and white South African women
12. Bone densitometry for clinical diagnosis and monitoring
13. Axial and appendicular bone density predict fractures in older women
14. Current methods and recent advances in the diagnosis of osteoporosis
15. Longitudinal precision of dual-energy X-ray absorptiometry via multicentre study
16. The Evaluation of Osteoporosis: Dual Energy X ray Absorptiometry in Clinical Practice
17. Short-term and long-term fracture prediction by bone mass measurement: A prospective study
18. Dual X-ray absorptiometry of the lumbar spine : The precision of paired anterior posterior/lateral studies
19. A comparison of lateral versus anterior-posterior spine dual energy X-ray absorptiometry for the diagnosis of osteopenia
20. Estimates of volumetric bone density from projectional measurements improve the discriminatory capability of dual X-ray absorptiometry
21. Effective dose values in bone mineral measurements by photon absorptiometry and computed tomography
22. Single X-ray absorptiometry of the forearm: Precision, correlation and reference data
23. Forearm BMD as measured by peripheral quantitative computed tomography (pQCT) in a German reference population
24. Perspectives: Ultrasound assessment of bone
25. Broadband ultrasound attenuation compared with dual-energy X-ray absorptiometry in screening for postmenopausal low bone density
26. Ultrasound velocity through bone predicts incident vertebral deformity
27. Comparison of speed of sound ultrasound with single photon absorptiometry for determining fracture odds ratios
28. Quantitative ultrasound and vertebral fracture in postmenopausal women
29. Reflection ultrasound velocities and histomorphometric and connectivity analyses: Correlations and effect of slow-release sodium fluoride
30. Non-invasive assessment of bone mineral and structure: State of the art
31. Site of osteodensitometry in perimenopausal women: Correlation and limits of agreement between anatomical regions
32. Sites of bone density measurement may affect therapy decisions
33. Proximal femur bone mineral levels of US adults
34. Bone density at various sites for the prediction of hip fractures
35. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
36. Prediction of vertebral and femoral strength in vitro by bone mineral density measured at different skeletal sites
37. The contribution of bone loss to postmenopausal osteoporosis
38. Variability of vertebral and femoral postmenopausal bone loss: A longitudinal study
39. Fast and slow bone losers: Relevance to the management of osteoporosis
40. Preventing osteoporotic fractures
41. Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease. Overall findings and differences by age for 316 099 white men
42. Bone densitometry in clinical practice
43. Guidelines for diagnosis and management of osteoporosis
44. Guidelines for the early detection of osteoporosis and prediction of fracture risk
45. Hypovitaminosis D in medical inpatients
46. Epidemiology and clinical features of osteoporosis in young individuals
47. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
48. Aminoterminal propeptide of type 1 collagen (PINP) is a more sensitive marker of bone turnover then C-t terminal propeptide in osteoporosis
49. The role of biochemical tests in the screening and monitoring of osteoporosis
50. The measurement of pyridinium cross-links: A methodological overview
51. Biochemical markers of bone resorption compared with estimates of bone resorption from radiotracer kinetic studies in osteoporosis
52. Molecular basis and clinical application of biological markers of bone turnover
53. The role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study
54. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
55. Low bone mass and fast rate of bone loss at menopause-equal risk factors for future fracture. A 15 year follow-up study
56. Bone resorption markers predict hip fracture risk in elderly women: The EPIDOS prospective study
57. Intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
58. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis
59. Bone turnover in postmenopausal osteoporosis: Effect of therapy
60. Effect of treatment with oral alendronate on bone mineral density and fracture incidence in postmenopausal osteoporosis
61. Biologic variation in urinary excretion of pyridinium cross-links: Recommendations for the optimum specimen
62. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino-acid sequence of the C-telopeptide of type 1 collagen
63. Risk factors for hip fracture in white women
64. Thinking straight about calcium
65. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women
66. Effect of calcium supplementation on bone loss in postmenopausal women
67. Preventing of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation, and hormone replacement therapy
68. Calcium for prevention of osteoporotic fractures in postmenopausal women
69. The effect of season and latitude on in vitro vitamin D formation by sunlight in South Africa
70. New concept of vitamin D efficacy in the elderly: 250HD improves body sway and thus reduces falls and hip fractures
71. Prevention of hip fractures in elderly women with vitamin D3 and calcium
72. Protein supplements increase serum insulin-like growth factor-1 levels and attenuate proximal femur bone loss in patients with recent hip fracture
73. Risk factors for the development of osteoporosis in a South African population
74. Bone changes after alcohol use
75. Epidemiology of osteoporosis and associated fractures
76. A prospective study of alcohol consumption and bone mineral density
77. Effects of alcohol ingestion on estrogens in postmenopausal women
78. The bone density of female twins discordant for tobacco use
79. Cigarette smoking, sex hormones and bone density in women
80. Prevention
81. Dimensions and estimated mechanical characteristics of the humerus after long-term tennis loading
82. Exercise: Moving in the right direction
83. Exercise-induced amenorrhoea and bone density
84. Glucocorticoid-induced osteoporosis: Pathogenesis and management
85. Risk of vertebral fractures in women with rheumatoid arthritis
86. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy
87. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: A double blind prospective comparison between prednisone and deflazacort
88. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
89. Vitamin D and calcium in the prevention of corticosteroid-induced osteoporos: A 3 year follow-up
90. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin
91. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
92. Preventing osteoporotic fractures
93. Falls in the nursing home
94. Fall direction, bone mineral density and function: Risk factors for hip fracture in frail nursing home elderly
95. Predictors for falls and fractures in the longitudinal aging study Amsterdam
96. Falls among community-dwelling elderly in Japan
97. Depression in the elderly - Falls and pitfalls
98. Prevention of spinal osteoporosis in oophorectomized women
99. Long-term estrogen therapy prevents bone loss and fracture
100. Hip fracture and the use of estrogens in postmenopausal women
101. Estrogen treatment of patients with established osteoporosis
102. Treatment of postmenopausal osteoporosis is with transdermal estrogen
103. Estrogen replacement therapy and fractures in older women
104. Estrogen and the risk of fracture - New data, new questions
105. Alendronate added to ongoing hormone replacement therapy in the treatment of osteoporosis: Effects on biochemical markers of bone turnover
106. Effects of alendronate and estrogen, alone or in combination, on bone mass and turnover in postmenopausal osteoporosis
107. Decreased mortality in users of estrogen replacement therapy
108. Hormone therapy to prevent disease and prolong life in postmenopausal women
109. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
110. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting
111. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
112. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
113. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
114. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and on 108 411 women without breast cancer
115. Update in women's health
116. Perimenopause: The complex endocrinology of the menopausal transition
117. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
118. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
119. Effects of raloxifene on serum lipids and coagulation factors in healty postmenopausal women
120. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women
121. Effect of tibolone on postmenopausal bone loss
122. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17β estradiol and dyhydrogesterone
123. Prevention of loss in late postmenopausal women
124. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2 year doubled-blind placebo- controlled study
125. Prevention of early postmenopausal bone loss with cyclical etidronate therapy
126. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
127. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracture
128. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
129. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
130. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
131. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin therapy
132. Calcitonin for prevention and treatment of osteoporosis
133. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin
134. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
135. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements
136. Fluoride: Mode of action
137. Fluoride therapy for the vertebral crush fracture syndrome
138. Fluoride and vertebral fractures
139. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial
140. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
141. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis
142. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis
143. Fluoride salts are not better at preventing new vertebral fractures than calcium - Vitamin D in postmenopausal osteoporosis: The FAVOS study
144. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis: A randomized, controlled trial
145. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate
146. Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy
147. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol
148. Randomized controlled study of effects of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
149. Is parathyroid hormone a therapeutic option for osteoporosis? Review of the clinical evidence
150. Strontium rarelate as a treatment of vertebral osteoporosis
151. Effects of nandrolone decanoate and anti-resorptive therapy on vertebral density in osteoporotic menopausal women
152. Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action
153. Alfacacidol (alpha D3) and calcium in osteoporosis
154. Treatment of postmenopausal osteoporosis with calcitriol or calcium
155. 1α Hydroxyvitamin D treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women
156. Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
157. The response to calcitriol therapy in postmenopausal osteoporotic women is a function of initial calcium absorptive status
158. Postmenopausal osteoporosis: No effect of three years treatment with 1,25 dihydroxycholecalciferol
159. Calcitriol is not effective in postmenopausal osteoporosis
160. A double-blind placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss
161. Effect of ipriflavone - A synthetic derivative of natural isoflavones on bone mass loss in the early years after menopause